Anavex Life Sciences Corp (AVXL)
3.82
-0.07
(-1.80%)
USD |
NASDAQ |
May 10, 16:00
3.82
0.00 (0.00%)
After-Hours: 19:39
Anavex Life Sciences Research and Development Expense (Quarterly): 8.684M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 8.684M |
| September 30, 2023 | 10.06M |
| June 30, 2023 | 10.28M |
| March 31, 2023 | 11.31M |
| December 31, 2022 | 12.07M |
| September 30, 2022 | 11.38M |
| June 30, 2022 | 9.273M |
| March 31, 2022 | 8.605M |
| December 31, 2021 | 8.656M |
| September 30, 2021 | 9.373M |
| June 30, 2021 | 8.964M |
| March 31, 2021 | 6.721M |
| December 31, 2020 | 7.926M |
| September 30, 2020 | 6.105M |
| June 30, 2020 | 6.725M |
| March 31, 2020 | 6.053M |
| December 31, 2019 | 6.349M |
| September 30, 2019 | 4.711M |
| June 30, 2019 | 5.758M |
| March 31, 2019 | 6.079M |
| December 31, 2018 | 5.712M |
| September 30, 2018 | 4.408M |
| June 30, 2018 | 2.998M |
| March 31, 2018 | 3.245M |
| December 31, 2017 | 2.694M |
| Date | Value |
|---|---|
| September 30, 2017 | 3.836M |
| June 30, 2017 | 2.300M |
| March 31, 2017 | 2.493M |
| December 31, 2016 | 2.042M |
| September 30, 2016 | 3.366M |
| June 30, 2016 | 1.159M |
| March 31, 2016 | 1.090M |
| December 31, 2015 | 1.164M |
| September 30, 2015 | 0.7465M |
| June 30, 2015 | 0.7995M |
| March 31, 2015 | 0.4071M |
| December 31, 2014 | 0.3186M |
| September 30, 2014 | 0.344M |
| June 30, 2014 | 0.265M |
| March 31, 2014 | 0.1182M |
| December 31, 2013 | 0.0052M |
| September 30, 2013 | 0.0973M |
| June 30, 2013 | 0.039M |
| March 31, 2013 | 0.0006M |
| December 31, 2012 | 0.127M |
| September 30, 2012 | 0.113M |
| June 30, 2012 | 0.394M |
| March 31, 2012 | 0.4296M |
| December 31, 2011 | 1.717M |
| September 30, 2011 | 0.5918M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.711M
Minimum
Sep 2019
12.07M
Maximum
Dec 2022
8.368M
Average
8.656M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Ventyx Biosciences Inc | 42.02M |
| Checkpoint Therapeutics Inc | 8.299M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |